z-logo
open-access-imgOpen Access
Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells
Author(s) -
Monika Hreusová,
Vojtěch Novohradský,
Lenka Marková,
Hana Kostrhunová,
Ivan Potočňák,
Viktor Brabec,
Jana Kašpárková
Publication year - 2022
Publication title -
bioinorganic chemistry and applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.865
H-Index - 35
eISSN - 1565-3633
pISSN - 1687-479X
DOI - 10.1155/2022/3095749
Subject(s) - rhabdomyosarcoma , cancer cell , cancer , chemistry , cancer research , cancer stem cell , biology , sarcoma , pathology , medicine , genetics
In this work, gallium(III) complex with cloxyquin (5-chloro-8-quinolinol, HClQ) ligands is shown to effectively inhibit proliferation of rhabdomyosarcoma cells, the frequent, aggressive, and poorly treatable cancer of children. It offers striking selectivity to cancer cells compared to noncancerous human fibroblasts. The data reveal that the complex induces ferroptosis in rhabdomyosarcoma cells, likely due to interfering with iron metabolism. Importantly, it can kill both bulk and stem rhabdomyosarcoma cells. To the best of our knowledge, this is the first compound based on metal other than Fe capable of inducing ferroptosis in cancer cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom